Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Executive summary

Burden of Treatment-resistant depression

5 evidence topics · 27 sources

Summary: definition and epidemiology

A consensus definition of TRD with demonstrated predictive utility does not currently exist. The FDA and EMA use inadequate response to a minimum of two antidepressants despite an adequate treatment trial and adherence, and ICER's draft scope population is adults with MDD for whom “two or more prior antidepressants prescribed at adequate dose and duration, during the current episode, have not resulted in adequate therapeutic benefit”. In the United States, a synthesis of 4 claims studies (Medicare, Medicaid, commercial plans, and the Veterans Health Administration) estimated 8.9 million adults with medication-treated MDD over 12 months, of whom 2.8 million (30.9%) had TRD; ICER cites the same 2.8 million. In 2025, 19.7 million adults aged 18 or older (7.4%) had a past-year major depressive episode, and 10.2 million of them (51.7%) took prescription medication for their mental health. In two cohorts, 10.4% of 230,801 people newly diagnosed and treated for depression developed TRD within 1 year, and 9.6% of 355,942 people with MDD met TRD criteria. Estimates depend on the definition: claims-based incidence varied 6-fold or 7-fold within a database across implementation choices, and real-world prevalence is estimated to range between 6 and 55%. In a cohort of 158 169 unipolar MDD episodes, 11% met TRD criteria.

Summary: natural history and mortality

QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% at the first to fourth acute treatment steps, and participants who required more steps had higher relapse rates during follow-up. A review of 9 outcome studies (1279 participants) found that as many as 80% of those requiring multiple treatments relapsed within a year of remission and that the probability of recovery within 10 years was about 40%. Under treatment as usual, 24-month response and remission rates were 18.4% (19/103) and 7.8% (8/103). In one cohort, TRD was associated with higher all-cause mortality than non-TRD MDD (adjusted HR 1.29; 95% CI 1.22–1.38). In a cohort of 139,753 people with TRD, suicide mortality was 0.14/100 person-years with TRD and 0.04/100 person-years with MDD alone, and ICER's draft scope states a “greater than 3-fold risk of death by suicide” than with non-TRD MDD. Another cohort reported an adjusted all-cause mortality HR of 1.35 (95% CI 1.21-1.50) and an external-cause mortality HR of 1.97. Another study reported an overall incidence of 0.47 completed and 4.66 attempted suicides per 100 patient years in TRD.

Summary: humanistic burden and long-term morbidity

In a study of 2467 participants (377 with TRD and 2090 without), those with TRD had lower SF-12 mental component scores (30 vs 45.7) and Q-LES-Q scores (43.6 vs 63.7), and WPAI overall work impairment of 52.9% versus 24.9%. A review of 62 articles found quality-of-life scores “.41±.8 and .26±.8 points lower” in TRD than in remission or response, respectively. In a cohort of 411 participants in seven European countries, mean EQ-5D-5L score at baseline was 0.41 and 30.2% were unemployed. ICER's 2019 esketamine model used utilities of 0.86 for no depression, 0.68 for mild to moderate depression, and 0.50 for severe depression. TRD is a risk factor for incident cardiovascular disease, type 2 diabetes mellitus, osteoporosis, and metabolic syndrome. In a cohort of 23,335 people with TRD, the hazard of cardiovascular death was higher (aHR 1.32) without additional overall risk of major adverse cardiovascular events. Compared with matched non-TRD episodes, TRD episodes had 132.3 versus 58.7 mean lost workdays in the 12 months after the index date.

Summary: economic burden and healthcare resource utilization

In the United States, the total annual burden of medication-treated MDD was estimated at $92.7 billion, of which $43.8 billion (47.2%) was attributable to TRD, including $25.8 billion of the health care burden. Four cohort studies report higher per patient per year health care costs with TRD than with non-TRD MDD: $6,709, an adjusted $3,377 (unadjusted totals $25,059 vs $19,945), US$4382, and $5,906 more. Participants with TRD who had work loss data (N = 1,908) had 35.8 work loss days per patient per year and $1,811 higher work loss costs than those with non-TRD MDD. In the study reporting the adjusted $3,377 difference, the TRD cohort had a higher rate of behavioral health-related inpatient visits than the non-TRD MDD cohort (IRR 1.49). A review of 62 articles found annual health care and lost productivity costs $5,481 and $4,048 higher, respectively, than in treatment-responsive depression, and estimated an added societal cost of $29-$48 billion per year. Across 12 studies, direct and indirect costs rose with increasing levels of non-response. Compared with matched non-TRD episodes, TRD episodes had 3.9 versus 1.3 mean inpatient bed-days in the 12 months after the index date.

Summary: burden on caregivers and families

Across all adults with MDD in the United States in 2019, an estimated 17 million household members without MDD lost $80.1 billion in annual income. In a caregiver survey (169 TRD caregivers and 1070 No TRD caregivers), TRD caregivers provided 23.3 versus 14.6 mean weekly caregiving hours. Adjusted annual indirect costs were $11,121 versus $7761, with presenteeism the largest component, and adjusted annual direct costs were $29,805 versus $20,642. More TRD caregivers reduced their work hours (29.0% vs 11.5%), took a leave of absence (11.1% vs 5.2%), had out-of-pocket caregiving expenses (45.5% vs 22.2%), and screened positive for depression (16.8% vs 6.7%). The survey was cross-sectional, used a convenience sample, and operationalized TRD by self-report with a tool not tested for reliability and validity. In a matched cohort, 2,359 first-born offspring of parents with TRD had adjusted hazard ratios of 4.6 for depression and 3.2 for suicide attempt, and their relative risks were similar to those of offspring of parents with other depression.